



PATENT
Attorney Docket No. 204133

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Roelvink et al.

Group Art Unit: 1648

Application No. 09/617,569

Examiner: S. Foley

Filed: July 17, 2000

For: ANTIGENIC COMPOUNDS AND METHODS

CLAIM AMENDMENTS OF OCTOBER 12, 2001, WITH NOTED CHANGES

1. (Amended) A complex comprising (a) a virion having a surface and a lumen and comprising viral capsid proteins, (b) at least one non-native ligand displayed on the surface, which at least one ligand recognizes an epitope present on an immune effector cell, ~~and~~ (c) at least one first nucleic acid encoding at least one first non-native antigen, and (d) at least one non-native second antigen displayed on the surface.

8. (Amended) The complex of claim 1[7], wherein at least one first antigen is the same as at least one second antigen.

9. (Amended) The complex of claim 1[7], wherein the virion comprises at least one chimeric protein comprising at least one first domain derived from a viral capsid protein and at least one second domain comprising at least one second antigen or at least one ligand.

26. (Amended) A method of immunizing a mammal, the method comprising introducing a complex comprising (a) a virion having a surface and a lumen and comprising viral capsid proteins, (b) at least one first nucleic acid encoding at least one first non-native antigen, and (c) at least one second non-native antigen displayed on the surface into a mammal under conditions sufficient for the mammal to mount at least one immune response to at least one of the antigens.

40. (Amended) A pharmaceutical composition comprising (a) the complex of claim 1 ~~[a complex which comprises (i) a virion having a surface and a lumen and comprising viral capsid proteins, (ii) at least one first nucleic acid encoding at least one first non-native antigen]~~, and (b) a physiologically-acceptable carrier.

44. (New) The pharmaceutical composition of claim 43, wherein at least one polypeptide comprises a domain derived from CD40-L or osteopontin.

In re Appln. of Roelvink et al.
Application No. 09/617,569

45. (New) The pharmaceutical composition of claim 43, wherein the polypeptide is a cytokine.

46. (New) The complex of claim 16, wherein at least one polypeptide is CD40-L.

47. (New) The complex of claim 16, wherein at least one polypeptide is osteopontin.

48. (New) The method of claim 23, wherein at least one polypeptide is CD40-L.

49. (New) The method of claim 23, wherein at least one polypeptide is osteopontin.

50. (New) The method of claim 30, wherein at least one polypeptide is CD40-L.

51. (New) The method of claim 30, wherein at least one polypeptide is osteopontin.